Incyte reported $26.11B in Market Capitalization this November of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.57B 100M Nov/2026
Agenus USD 128M 21M Mar/2026
Agios Pharmaceuticals USD 1.61B 598M Nov/2026
Alnylam Pharmaceuticals USD 33.02B 7.17B Sep/2026
Amgen USD 247.94B 20.06B Nov/2026
BioCryst Pharmaceuticals USD 2.54B 880M Jun/2026
Biogen USD 33.38B 1.48B Sep/2026
BioMarin Pharmaceutical USD 10.68B 936M Nov/2026
Bristol-Myers Squibb USD 127.46B 9.81B Sep/2026
Eli Lilly USD 1.09T 40.33B Sep/2026
Exelixis USD 19.82B 5.34B Nov/2026
Gilead Sciences USD 184.82B 27.96B Sep/2026
Incyte USD 24.6B 1.95B Sep/2026
Ionis Pharmaceuticals USD 4.24B 3.18B Nov/2026
MacroGenics USD 151M 143M Nov/2026
Merck USD 375.59B 17.09B Nov/2026
Moderna USD 99.14B 22.26B Nov/2026
Nektar Therapeutics USD 2.12B 1.26B Mar/2026
Neurocrine Biosciences USD 16.38B 1.96B Nov/2026
Novartis USD 292.09B 51.5B Sep/2026
Novartis USD 328.21B 54.92B Nov/2026
Pfizer USD 165.12B 1.71B Nov/2026
Sarepta Therapeutics USD 1.65B 276M Nov/2026
Ultragenyx Pharmaceutical USD 1.37B 108M Nov/2026
Vertex Pharmaceuticals USD 140.44B 7.93B Nov/2026